Edition:
United Kingdom

Caladrius Biosciences Inc (CLBS.OQ)

CLBS.OQ on NASDAQ Stock Exchange Capital Market

4.28USD
23 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$4.28
Open
$4.31
Day's High
$4.31
Day's Low
$4.28
Volume
392
Avg. Vol
9,531
52-wk High
$7.75
52-wk Low
$2.65

Chart for

About

Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company's lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with... (more)

Overall

Beta: 1.58
Market Cap(Mil.): $32.35
Shares Outstanding(Mil.): 8.91
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Caladrius Biosciences Entered Common Stock Sales Agreement With H.C. Wainwright & Co

* CALADRIUS BIOSCIENCES INC - ENTERED INTO A COMMON STOCK SALES AGREEMENT WITH H.C. WAINWRIGHT & CO HAVING AGGREGATE OFFERING PRICE OF UP TO $12 MILLION Source text: (http://bit.ly/2ER7sY9) Further company coverage:

08 Feb 2018

BRIEF-Caladrius Biosciences reports 2017 third quarter results

* Q3 loss per share $0.38 from continuing operations Source text for Eikon: Further company coverage:

09 Nov 2017

BRIEF-Caladrius Biosciences files for resale of co's common stock‍​ by the selling stockholders

* Files for resale of up to 932,204 shares of Co's common stock‍​ by the selling stockholders - SEC filing Source text for Eikon: Further company coverage:

06 Sep 2017

Earnings vs. Estimates